Literature DB >> 10233693

Human eotaxin induces eosinophil extravasation through rat mesenteric venules: role of alpha4 integrins and vascular cell adhesion molecule-1.

K Nagai1, S Larkin, A Hartnell, K Larbi, M Razi Aghakhani, C Windley, D Davies, R R Lobb, T J Williams, S Nourshargh.   

Abstract

Eotaxin is a potent eosinophil-specific CC-chemokine, which has been shown to play a role in the selective induction of eosinophil accumulation in a number of allergic models of inflammation. Many aspects of the mechanism by which eotaxin induces eosinophil accumulation in vivo remain unresolved. In the present study, we investigated the direct effect of synthetic human eotaxin on leucocyte/endothelial cell interactions within rat mesenteric venules, as quantified by intravital microscopy. Topical eotaxin (30 pmol) induced rapid firm adhesion and extravasation of leucocytes within the rat mesentery, the extravasated leucocytes all being eosinophils, as determined by histological analysis. Whilst eotaxin was unable to stimulate the interaction of rat eosinophils with vascular cell adhesion molecule-1 (VCAM-1) under static conditions in vitro, eotaxin-induced responses in vivo were significantly suppressed by anti-alpha4 integrin and anti-VCAM-1 monoclonal antibodies (mAbs). The anti-alpha4 integrin mAb, HP2/1 (3.5 mg/kg), inhibited the eotaxin-induced firm adhesion and extravasation, 60 min postapplication of the chemokine, by 89% and 84%, respectively. In the same set of experiments, the anti-VCAM-1 mAb, 5F10 (3.5 mg/kg), inhibited leucocyte adhesion and extravasation by 61% and 63%, respectively. These results demonstrate that eotaxin-induced migration of eosinophils through rat mesenteric venules in vivo is dependent on an alpha4 integrin/VCAM-1 adhesion pathway, the significance of which may only be evident under flow conditions and/or following the ligation of other adhesion molecules expressed on eosinophils.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233693      PMCID: PMC2326743          DOI: 10.1046/j.1365-2567.1999.00673.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane.

Authors:  M W Wakelin; M J Sanz; A Dewar; S M Albelda; S W Larkin; N Boughton-Smith; T J Williams; S Nourshargh
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

2.  E-selectin preferentially supports neutrophil but not eosinophil rolling under conditions of flow in vitro and in vivo.

Authors:  P Sriramarao; C R Norton; P Borgstrom; R G DiScipio; B A Wolitzky; D H Broide
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

3.  Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein.

Authors:  K Tenscher; B Metzner; E Schöpf; J Norgauer; W Czech
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

4.  Eotaxin-induced eosinophil migration in the peritoneal cavity of ovalbumin-sensitized mice: mechanism of action.

Authors:  A M Das; R J Flower; M Perretti
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

5.  Neutrophil CD18-dependent arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow can be activated through L-selectin.

Authors:  P K Gopalan; C W Smith; H Lu; E L Berg; L V McIntire; S I Simon
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

6.  Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors.

Authors:  J A Gonzalo; C M Lloyd; L Kremer; E Finger; C Martinez-A; M H Siegelman; M Cybulsky; J C Gutierrez-Ramos
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

7.  Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice.

Authors:  M E Rothenberg; R Ownbey; P D Mehlhop; P M Loiselle; M van de Rijn; J V Bonventre; H C Oettgen; P Leder; A D Luster
Journal:  Mol Med       Date:  1996-05       Impact factor: 6.354

8.  Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response.

Authors:  J A Ganzalo; G Q Jia; V Aguirre; D Friend; A J Coyle; N A Jenkins; G S Lin; H Katz; A Lichtman; N Copeland; M Kopf; J C Gutierrez-Ramos
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

9.  Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia.

Authors:  E A Garcia-Zepeda; M E Rothenberg; R T Ownbey; J Celestin; P Leder; A D Luster
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

10.  T cell-dependent regulation of eotaxin in antigen-induced pulmonary eosinophila.

Authors:  J A MacLean; R Ownbey; A D Luster
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  2 in total

1.  VCAM-1 contributes to rapid eosinophil accumulation induced by the chemoattractants PAF and LTB4: evidence for basal expression of functional VCAM-1 in rat skin.

Authors:  D Davies; K Larbi; A Allen; M Sanz; V B Weg; D O Haskard; R R Lobb; S Nourshargh
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

2.  South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.

Authors:  Simone I Richardson; Elin S Gray; Nonhlanhla N Mkhize; Daniel J Sheward; Bronwen E Lambson; Constantinos Kurt Wibmer; Lindi Masson; Lise Werner; Nigel Garrett; Jo-Ann S Passmore; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson; Penny L Moore; Lynn Morris
Journal:  Retrovirology       Date:  2015-06-24       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.